This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Myovant Sciences Management

Management criteria checks 3/4

Key information

Dave Marek

Chief executive officer

US$6.2m

Total compensation

CEO salary percentage	12.0%
CEO tenure	2.2yrs
CEO ownership	0.1%
Management average tenure	4.3yrs
Board average tenure	3.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Dave Marek's remuneration changed compared to Myovant Sciences's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2022	n/a	n/a	-US$184m
Sep 30 2022	n/a	n/a	-US$190m
Jun 30 2022	n/a	n/a	-US$166m
Mar 31 2022	US$6m	US$750k	-US$206m
Dec 31 2021	n/a	n/a	-US$228m
Sep 30 2021	n/a	n/a	-US$238m
Jun 30 2021	n/a	n/a	-US$284m
Mar 31 2021	US$10m	US$151k	-US$255m

Compensation vs Market: Dave's total compensation ($USD6.25M) is above average for companies of similar size in the German market ($USD2.40M).

Compensation vs Earnings: Dave's compensation has been consistent with company performance over the past year.

CEO

Dave Marek (57 yo)

2.2yrs

Tenure

US$6,247,509

Compensation

Mr. David C. Marek, also known as Dave, has been Director of Myovant Sciences Ltd. since January 4, 2021 and served as its Principal Executive Officer. He had been Chief Commercial Officer of Axsome Therap...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
David Marek	CEO & Director	2.2yrs	US$6.25m	0.098% $ 2.6m
Uneek Mehra	Principal Financial Officer	1.5yrs	US$5.16m	0% $ 0
Lauren Merendino	Chief Commercial Officer	1.9yrs	US$3.47m	0.022% $ 587.9k
Matthew Lang	General Counsel & Corporate Secretary	5.7yrs	US$2.83m	0% $ 0
Albert Liao	Director of Corporate Communications	no data	no data	no data
Ann Tomlin	Senior Vice President of Human Resources	less than a year	no data	no data
Bryan Selby	Senior Vice President of Product Development	6.6yrs	no data	no data
Juan Camilo Ferreira	Chief Medical Officer	5.7yrs	US$1.98m	0.089% $ 2.3m
Andria Langenberg	Head of Drug Safety & Pharmacovigilance	5.7yrs	no data	no data
Jeffrey Nornhold	Senior VP of Pharmaceutical Operations & Development	4.3yrs	no data	no data

4.3yrs

Average Tenure

52yo

Average Age

Experienced Management: 71M's management team is considered experienced (4.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
David Marek	CEO & Director	2.2yrs	US$6.25m	0.098% $ 2.6m
Myrtle Potter	Chairman of the Board	4.5yrs	US$376.79k	0% $ 0
Terrie Curran	Independent Director	6.3yrs	US$363.33k	0% $ 0
Adele Gulfo	Director	3.3yrs	US$341.79k	0% $ 0
Mark Guinan	Lead Independent Director	4.7yrs	US$369.95k	0% $ 0
Shigeyuki Nishinaka	Non Independent Director	less than a year	no data	no data
Nancy Valente	Independent Director	1.3yrs	US$567.05k	0% $ 0

3.3yrs

Average Tenure

59yo

Average Age

Experienced Board: 71M's board of directors are considered experienced (3.3 years average tenure).

This company listing is no longer active

Myovant Sciences Management

Management criteria checks 3/4

Key information

Recent management updates

Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources

Myovant Sciences Ltd. Appoints Shigeyuki Nishinaka as Director

Principal Financial Officer recently sold €174k worth of stock

General Counsel & Corporate Secretary recently sold €559k worth of stock

Myovant Sciences Ltd., Annual General Meeting, Oct 21, 2022

CEO & Director recently sold €141k worth of stock

Recent updates

Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources

Myovant Sciences Ltd. Appoints Shigeyuki Nishinaka as Director

Myovant May Delist from the New York Stock Exchange

Myovant May Delist from the New York Stock Exchange

Sumitovant Biopharma Ltd. entered into a non-binding proposal to acquire Myovant Sciences Ltd. (NYSE:MYOV) for $1.2 billion.

Principal Financial Officer recently sold €174k worth of stock

General Counsel & Corporate Secretary recently sold €559k worth of stock

Myovant Sciences and Pfizer Inc. Receive U.S. FDA Approval of MYFEMBREE®, A Once-Daily Treatment for the Management of Moderate to Severe Pain Associated with Endometriosis

First quarter 2023 earnings released: US$0.22 loss per share (vs US$0.67 loss in 1Q 2022)

Myovant Sciences Ltd., Annual General Meeting, Oct 21, 2022

CEO & Director recently sold €141k worth of stock

Myovant Sciences and Pfizer Inc. Announce Results of the Phase 3 Spirit 1 and Spirit 2 Studies of Investigational Once-Daily Relugolix Combination Therapy

Myovant Sciences and Pfizer Inc. Announce FDA Acceptance of Supplemental New Drug Application for Myfembree

No longer forecast to breakeven

Full year 2022 earnings released: US$2.22 loss per share (vs US$2.83 loss in FY 2021)

Myovant Sciences Ltd. Announces European Commission Approval for Orgovyx (Relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer

Less than half of directors are independent

General Counsel & Corporate Secretary recently sold €77k worth of stock

Myovant Sciences Receives Positive CHMP Opinion for Orgovyx® (Relugolix) for the Treatment of Advanced Prostate Cancer

Forecast to breakeven in 2024

CEO & Director recently sold €257k worth of stock

Myovant Sciences Ltd. Provides Revenue Guidance for the Three Months Ended December 31, 2021

General Counsel & Corporate Secretary recently sold €64k worth of stock

General Counsel & Corporate Secretary recently sold €124k worth of stock

Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis

Less than half of directors are independent

Key Executive recently sold €60k worth of stock

Myovant Sciences and Pfizer Inc. Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids

Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids

The U.S. Food and Drug Administration Informs Myovant Sciences Ltd. by Teleconference That They Have Placed A Partial Clinical Hold on the Phase 3 Serene Study (MVT-601-050)

General Counsel & Corporate Secretary recently sold €171k worth of stock

New 90-day low: €16.40

Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 Liberty Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids

Myovant Sciences and Pfizer Inc Announces Positive Data from Phase 3 SPIRIT Extension Study of Relugolix Combination Therapy in Women with Endometriosis

Myovant Sciences Announces U.S. Availability of ORGOVYX™ for the Treatment of Advanced Prostate Cancer

Myovant Sciences Ltd Appoints David Marek as Principal Executive Officer and Member of the Board of Directors

Myovant Sciences Ltd. and Pfizer Inc. Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’S Health

Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer

New 90-day high: €21.40

New 90-day high: €20.00

Myovant Sciences Announces Results of Additional Secondary Endpoint of Castration Resistance-Free Survival from Phase 3 HERO Study of Relugolix in Advanced Prostate Cancer

Myovant Sciences Launches 'Forward for Health Equity' Grant Program to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids

New 90-day high: €19.40

Myovant Sciences Presents Additional Data on Bone Mineral Density in Women with Uterine Fibroids from Phase 3 Liberty Program and from Prospective Observational Study

Insider recently sold €113.0k worth of stock

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age